Vitality Watch

Dossier pubmed preclinical 04-nov-2026
Animal model, organoid, or cell-culture result — not yet human

GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.

Key claim: Direct exposure to semaglutide or GIP does not induce atrophy-related gene expression or impair myogenesis in primary human myotubes, indicating that incretin-associated lean mass loss is an indirect consequence of caloric restriction rather than direct myotoxicity.

Abstract

GLP-1 and GIP/GLP-1 receptor agonists produce substantial weight loss in clinical trials but significant loss of lean body mass is reported. Whether this reflects a direct pharmacological effect on skeletal muscle or an indirect consequence of caloric restriction and reduced mechanical loading is unknown. Primary myoblasts were isolated from skeletal muscle of older adults with obesity undergoing orthopaedic surgery. GIPR and GLP-1R expression was characterised by RT-qPCR and flow cytometry. Differentiated myotubes were treated with semaglutide or GIP peptide and assessed for atrophy-related gene expression (qPCR), secretome perturbation (Olink Reveal), mitochondrial and glycolytic bioenergetics (Seahorse XF Real-Time ATP Rate Assay, glucose uptake, lactate secretion) and myotube morphology and myogenesis (immunofluorescence). GIPR mRNA was consistently detected across all donors; GLP-1R mRNA was undetectable by PCR, though LUXendin645 flow cytometry in a subset of three donors identified low-level surface GLP-1R protein in 51-66% of myoblasts. Neither semaglutide nor GIP altered atrophy-related gene expression or the secretome, with no proteins reaching significance. Semaglutide reduced glycolytic and total ATP production rates, accompanied by reduced lactate secretion, suggesting modest suppression of glycolytic flux; mitochondrial parameters were unaffected. Neither treatment impaired myotube thickness or differentiation; GIP increased myotube thickness after 8 days. Direct GLP-1 and GIP receptor activation did not produce major atrophic, inflammatory, morphological, myogenic, or mitochondrial effects on primary human skeletal muscle myotubes. These findings are consistent with an indirect mechanism underlying the lean mass loss observed with incretin-based therapies, a question of particular relevance as these agents are increasingly used in older adults at risk of sarcopenia.

Why this matters

For the AOM-as-longevity narrative, this cell-culture finding [mechanism-plausible] narrows a proposed harm mechanism: direct semaglutide or GIP exposure did not trigger the measured atrophy signals or impair myogenesis under the tested conditions. It does not establish that clinical lean-mass loss is exclusively indirect, demonstrate preserved strength or function, or establish generalized longevity benefit; trend trajectory is unchanged because the finding supplies no media/community evidence of spread.

Source

Link

Briefing card

GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
Stage: preclinical · pubmed · 04-nov-2026

If you take semaglutide, this muscle-cell study found no direct atrophy signaling under the tested conditions, but it does not establish that your muscle mass or strength will be preserved.

Direct exposure to semaglutide or GIP does not induce atrophy-related gene expression or impair myogenesis in primary human myotubes, indicating that incretin-associated lean mass loss is an indirect consequence of caloric restriction rather than direct myotoxicity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11357-026-02625-w

build build 880 · 2bcef25 · 2026-11-18